Glioblastoma Multiforme Treatment Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Glioblastoma Multiforme Treatment Market, By Treatment
7.1. Glioblastoma Multiforme Treatment Market, by Treatment, 2021-2030
7.1.1. Surgery
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Radiation Therapy
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Chemotherapy
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Targeted Therapy
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Tumor Treating Field (TTF) Therapy
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Immunotherapy
7.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Glioblastoma Multiforme Treatment Market, By Drug Class
8.1. Glioblastoma Multiforme Treatment Market, by Drug Class, 2021-2030
8.1.1. Temozolomide
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Bevacizumab
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Lomustine
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Carmustine Wafers
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Glioblastoma Multiforme Treatment Market, By End User
9.1. Glioblastoma Multiforme Treatment Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Clinics
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Ambulatory Surgical Centers
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Glioblastoma Multiforme Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Amgen, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pfizer Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Amgen, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Teva Pharmaceutical Industries Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sun Pharmaceutical Industries Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Arbor Pharmaceuticals, LLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Amneal Pharmaceuticals
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Karyopharm Therapeutics, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers